Survey

Fingolimod (Gilenya) was recently FDA approved in the treatment of relapsing remitting multiple sclerosis (RRMS). How is your health system covering or planning on covering this new oral disease-modifying therapy (DMT)?

1) We will be/are covering it only for patients who have failed injectable DMTs (both in the interferon class and glatiramer acetate).

2) We will be/are covering it only for patients who have failed injectable DMTs (either an interferon or glatiramer acetate).

3) We will be/are covering it for patients that meet certain criteria. However, the main criteria does not have to be failure of an injectable DMT.

4) We will be/are covering it for patients with a new diagnosis of RRMS only.

5) We will not be covering it at all until more data is available.

6) We have not yet decided how to cover this product.

Digital Edition

Tocilizumab approved for treatment
of SJIA

To confirm your e-newsletter subscription click here.

To ensure future delivery of email newsletters from Formulary, please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff

FDA approves rituximab to treat rare disorders

Topical diclofenac beats oral formulation in safety, tolerability

Topical diclofenac is safer and better tolerated by patients with osteoarthritis of the knee compared with the oral formulation, according to data presented here at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md. Read full article.

Successful switch to transdermal buprenorphine for OA pain of the hip, knee

Conversion to a 7-day regimen of transdermal buprenorphine (Butrans Transdermal System, Purdue Pharma) from a stable regimen of hydrocodone/acetaminophen (Vicodin, Abbott) can be successful in patients with osteoarthritic pain of the hip or knee, according to a study presented at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md. Read full article.

Capsaicin patch reduces neuropathic pain of HIV-associated neuropathy

One 30-minute application of a capsaicin (8%) patch (NGX-4010, Qutenza, NeurogesX) can reduce neuropathic pain due to HIV-associated neuropathy, according to data presented here at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md. Read full article.

Transdermal buprenorphine effective for moderate-to-severe chronic low back pain

Transdermal buprenorphine (Butrans Transdermal System, Purdue Pharma) was superior to placebo in treating opioid-naïve patients with moderate-to-severe chronic low back pain, according to study results presented at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md. Read full article.

Top 5 Web Stories

1. Ceftaroline: A novel cephalosporin with methicillin-resistant Staphylococcus aureus and multidrug-resistant Streptococcus pneumoniae activity
   
   
2. Treatment of bipolar disorder: A focus on medication therapy for mania
   
   
3. Vilazodone hydrochloride (Viibryd): A selective serotonin reuptake inhibitor and partial 5HT1A receptor agonist for the treatment of major depressive disorder
   
   
4. Fentanyl sublingual tablets (Abstral): An opioid analgesic for the management of breakthrough pain in cancer patients
   
   
5. FDA Pipeline Preview, March 2011 (Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib)